Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has, of course, returned. But what can you do? The world keeps spinning which, after all, is a good thing. So with this glass-half-full approach in mind, time to fire up the coffee kettle, quaff a cup or three of stimulation, and dig in for another busy day. On that note, here are some tidbits. Hope your journey progresses nicely and, as always, do keep in touch …

Novartis (NVS) is abandoning an effort to gain U.S. regulatory approval for a biosimilar of Rituxan, a Roche (RHHBY) drug to treat certain cancer and rheumatoid arthritis. The decision comes after the Food and Drug Administration sought additional information to support the medicine, which is already approved in the European Union, Switzerland, Japan, and Australia. Rituxan is a monoclonal antibody used in non-Hodgkin’s lymphoma and rheumatoid arthritis; it had more than $4 billion in sales in the U.S. in 2016.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy